Editas Medicine

In News

Editas Medicine, Inc. (EDIT) stock price, news, quote and history - Yahoo Finance Australia

Yahoo Finance Australia - Oct 15, 2026

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference - GlobeNewswire

GlobeNewswire - Oct 14, 2026

A delivery method generated engineered immune cells inside the body and depleted B cells. - Stock Titan

Stock Titan - Oct 14, 2026

Editas Medicine (NASDAQ:EDIT) Stock Breaks Below 50 Day Moving Average - Here's Why - MarketBeat

MarketBeat - Oct 17, 2026

Editas Medicine to present gene editing research at ESGCT congress - Investing.com

Investing.com - Oct 14, 2026

Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions - Simply Wall Street

Simply Wall Street - Oct 08, 2026

Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift - Seeking Alpha

Seeking Alpha - Oct 12, 2026

Editas Medicine Receives Approval in Australia for Phase 3 Trial of EDIT-401 to Treat Hyperlipidemia - Yahoo Finance

Yahoo Finance - Oct 08, 2026

Editas Medicine Q3 2026 Earnings Date and Estimates - MarketBeat

MarketBeat - Oct 13, 2026

Editas Medicine Announces Second Quarter 2026 Results and Business Updates - GlobeNewswire

GlobeNewswire - Aug 05, 2026

Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401 - Yahoo Finance

Yahoo Finance - Oct 08, 2026

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia - GlobeNewswire

GlobeNewswire - Oct 08, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment